GLP-1 receptor agonists have already earned their place in mainstream medicine as effective, well-studied treatments for type 2 diabetes and obesity. Various studies have demonstrated the bounteous clinical benefit of this class of medicines. But as adoption of GLP-1s has surged, so has a wave of research pointing to benefits well beyond their original indications – effects that health system leaders and clinicians alike may not have anticipated when these medications first came to market.
From oncology to behavioral health to spine surgery, early studies are beginning to suggest that GLP-1s may be doing far more than managing weight and glucose. The impacts of these potential new uses – which, admittedly, remain in early stages – could have significant consequences for care planning in hospitals and health systems.
What Are the New Use Cases for GLP-1s?
The first, and perhaps most striking, use case comes from oncology. A Penn Medicine study retrospectively analyzed health records from over 111,000 women ages 45–80 and found that GLP-1 users had roughly 30% to 35% lower odds of developing breast cancer than non-users, a pattern that held even after matching for age, race, BMI, breast density, and diabetes status. Granted, the study is observational, not causal, and didn't account for drug type, duration of use, or genetic risk. Nevertheless, it's compelling early evidence that a drug built to manage weight may be able to moonlight as a cancer-prevention tool.
The oncology signal isn't an isolated curiosity, with similar data now emerging in behavioral health. A large study published in The BMJ, using VA health records on more than 600,000 veterans with type 2 diabetes, found that those on GLP-1 agonists had meaningfully lower risk of developing alcohol, cannabis, cocaine, nicotine, opioid, and other substance use disorders compared to those started on SGLT-2 inhibitors.
Among patients with pre-existing substance use disorders, GLP-1 use was also associated with lower mortality and reduced ER visits, hospitalizations, and overdoses – effects that were consistent across demographic subgroups. Like the Penn Medicine oncology study, these results are preliminary and observational; however, they are still strong, and particularly surprising. A medicine that can function as not just a tool of physical health, but also of mental health, would have profound clinical implications.
Finally, GLP-1s are reshaping conversations around surgical safety and recovery. A study in The Spine Journal that looked at nearly 21,000 patients with diabetes and/or obesity found that GLP-1 users had lower rates of extended hospital stays after undergoing one- or two-level anterior cervical discectomy and fusion (ACDF) surgery. Researchers found no increase in pulmonary aspiration and no difference in nonunion rates compared to matched non-users. The findings are reassuring from a safety standpoint and suggest a modest recovery benefit, but the study's authors were explicit that more data is needed before drawing firm conclusions about GLP-1s' role in surgical outcomes.
Taken together, these three studies spanning cancer prevention, addiction medicine, and spine surgery paint a picture of a drug class whose reach is expanding faster than many healthcare leaders can keep pace with.
Why Should Health Systems Monitor New GLP-1 Indications?
As research advances on GLP-1 benefits, cost remains a major unknown. Medicare is already paying an estimated $27.5 billion a year for non-weight loss indications, so no one can say how public and private payers will ultimately deal with new use cases. But utilization is growing regardless, and the base case is probably a less obese population for the foreseeable future.
What will that mean for hospitals and health systems? Purely as a weight-loss medication, GLP-1s are changing utilization from the OR to the ED. Take metabolic bariatric surgery (MBS), for instance, long a reliable revenue generator for many hospitals. A 2026 Harvard study found that MBS procedures declined by 34.1% between 2022 and 2024, while GLP-1 usage increased by 140.4%.
Almost all health system leaders are struggling already to understand the business implications of a less obese population, but truly strategic leaders should start to consider the possible impact of novel use cases, like the ones discussed above. Fewer oncology infusions, reduced ED utilization, shorter post-surgery hospital stays – all of these would have implications for health system strategy.
- If the oncology signal holds up in prospective trials, GLP-1 use could become a documented risk modifier, similar to BRCA status or family history. That could affect screening protocols, high-risk clinics, and payer risk models.
- If the behavioral health signal holds up – showing reduced ED visits, admissions, and mortality tied to substance use disorders – then GLP-1 use could become an important lever in total cost of care, especially for health systems with ACOs or other risk-based reimbursement.
- If the perioperative signal is backed up by additional data, then GLP-1 use could become a factor in bed planning, particularly for hospitals that have a robust spinal surgery program.
Ultimately, the evidence presented above is preliminary, and the perceived benefits may not survive additional study. But as GLP-1s evolve, healthcare leaders should closely monitor emerging use cases and their likely impact on established service lines.
